DUBLIN, June 26,
2024 /CNW/ -- Medtronic plc (NYSE: MDT), a
global leader in healthcare technology, today announced that
Karen Parkhill will resign as
executive vice president and chief financial officer to accept the
role of chief financial officer for HP Inc.
"On behalf of our employees, our executive committee and our
board of directors, I want to thank Karen for her leadership over
the last eight years. I am personally grateful to Karen for her
support through my transition to CEO, navigating the pandemic and
delivering a new operating model for the company. We wish her all
the best as she takes on the next chapter of her career," said
Geoff Martha, Medtronic chairman and
chief executive officer. "Across the company, we're building
momentum with our innovation-driven growth strategy, and we remain
focused and committed to delivering on our short- and longer-term
financial objectives."
"It has been a pleasure to serve Medtronic and our Mission for
the last eight years," said Parkhill. "I am grateful to have had
the opportunity to lead the outstanding finance team at Medtronic,
and I know they will continue to deliver on our commitments. I
remain excited about the plans Medtronic has for the future, and
most of all, the huge impact Medtronic technologies will have on
the lives of patients around the world."
The company is evaluating internal and external succession
candidates. Parkhill will continue to serve as chief financial
officer until her departure on August
2, and Gary Corona, senior
vice president, Global Financial Planning and Analysis, will serve
as interim chief financial officer upon her departure.
In addition, the company also reaffirmed guidance for its first
quarter and full fiscal year 2025, as previously disclosed in its
May 23, 2024, earnings press release
and webcast.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc,
headquartered in Dublin, Ireland,
is the leading global healthcare technology company that boldly
attacks the most challenging health problems facing humanity by
searching out and finding solutions. Our Mission — to alleviate
pain, restore health, and extend life — unites a global team of
95,000+ passionate people across more than 150 countries. Our
technologies and therapies treat 70 health conditions and include
cardiac devices, surgical robotics, insulin pumps, surgical tools,
patient monitoring systems, and more. Powered by our diverse
knowledge, insatiable curiosity, and desire to help all those who
need it, we deliver innovative technologies that transform the
lives of two people every second, every hour, every day. Expect
more from us as we empower insight-driven care, experiences that
put people first, and better outcomes for our world. In everything
we do, we are engineering the extraordinary. For more information
on Medtronic, visit www.Medtronic.com and follow Medtronic on
LinkedIn.
Forward-looking statements
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, which are subject
to risks and uncertainties, including risks related to competitive
factors, difficulties and delays inherent in the development,
manufacturing, marketing and sale of medical products, government
regulation, geopolitical conflicts, general economic conditions,
and other risks and uncertainties described in the company's
periodic reports on file with the U.S. Securities and Exchange
Commission including the most recent Annual Report on Form 10-K of
the company. Medtronic does not undertake to update its
forward-looking statements, including to reflect future events or
circumstances.
Contacts:
|
|
|
|
Erika Winkels
|
Ryan
Weispfenning
|
Public Relations
|
Investor
Relations
|
+1 (763) 526-8478
|
+1 (763)
505-4626
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-departure-of-karen-parkhill-chief-financial-officer-302182527.html
SOURCE Medtronic plc